<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303819</url>
  </required_header>
  <id_info>
    <org_study_id>20131212</org_study_id>
    <nct_id>NCT04303819</nct_id>
  </id_info>
  <brief_title>The Effect of Exenatide on Fasting Bile Acids</brief_title>
  <official_title>The Effect of Exenatide on Fasting Bile Acids in Newly Diagnosed Type 2 Diabetes Mellitus Patients, a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective
      analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were compared
      before and after exenatide treatment and correlation analysis between changes of FTBAs and
      glycemic parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective
      analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were tested
      at baseline. Then exenatide were applied to the T2DM participants for 12 weeks. FTBAs and
      glycemic parameters were measured again after exenatide treatment, and correlation analysis
      between changes of FTBAs and glycemic parameters were conducted to investigate the role of
      BAs in the glycemic control effect of exenatide.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2020</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma total bile acids in fasting state</measure>
    <time_frame>12 weeks</time_frame>
    <description>reported in μmol/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting plasma glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>reported in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin A1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>reported in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>12 weeks</time_frame>
    <description>reported in mU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum insulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>reported in mU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mess index</measure>
    <time_frame>12 weeks</time_frame>
    <description>reported in kg/m^2</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">38</enrollment>
  <condition>Type 2 Diabetes Mellitus in Obese</condition>
  <arm_group>
    <arm_group_label>newly diagnosed T2DM participants</arm_group_label>
    <description>newly diagnosed T2DM participants without anti-diabetic drugs intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide treatment</intervention_name>
    <description>12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.</description>
    <arm_group_label>newly diagnosed T2DM participants</arm_group_label>
    <other_name>exenatide</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed T2DM patients

        Exclusion Criteria:

          -  History of hepatobiliary or pancreatic diseases

          -  History of anti-diabetic drugs intake

          -  Change of anti-dyslipidemia therapy regimen

          -  Estimated glomerular filtration rate less than 60 mL/min/1.73 m^2

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boyu Li, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chao-yang hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Lihong Liu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

